#204 NephMadness 2020: SGLT2 Inhibitors

<p>Get under the hood of SGLT2 inhibitors! Listen as our guests Dr. Harish Seethapathy, Dr. Matt Sparks, and Dr. Joel Topf give us a tour through the NephMadness 2020 SGLT2i region! How do these promising drugs work, and what evidence is there for using them in non-diabetic kidney disease or kidney transplant patients. <a href="https://thecurbsiders.com/episode-list">Show Notes</a> | <a href="https://open.spotify.com/show/3SKlzOLxyztvA1BkJfnf67">Spotify</a> | <a href="https://www.teepublic.com/user/kashlakmemorial">Swag!</a> | <a href="https://thecurbsiders.com/top-picks">Top Picks</a> | <a href="https://thecurbsiders.com/knowledgefood">Mailing List</a> | <a href="mailto:thecurbsiders@gmail.com">thecurbsiders@gmail.com</a></p> <h3><br> </h3> <h3><strong>Credits</strong></h3> <ul> <li>Written and Produced by: Hannah R. Abrams<br> </li> <li>Cover Art and Infographic by: Hannah R. Abrams<br> </li> <li>Hosts: Hannah R Abrams, Matthew Watto MD, FACP<br> </li> <li>Editor: Clair Morgan of <a href="http://Nodderly.com">Nodderly.com</a> (audio), Emi Okamoto MD (written)<br> </li> <li>Guests: Harish Seethapathy MD; Matthew Sparks MD; Joel Topf MD<br> </li> </ul> <h3><br> </h3> <h3><strong>Sponsor: McGraw Hill</strong></h3> <h3><br> </h3> <h3><br> </h3> <h3><strong>Time Stamps</strong></h3> <ul> <li> <strong>00:00</strong> Sponsor<br> </li> <li> <strong>00:26</strong> Intro, disclaimer, guest bio<br> </li> <li> <strong>02:57</strong> Guest one-liner and <strong>Picks of the Week*:</strong> Michael Pollan audiobook on Coffee and Caffeine Addiction<br> </li> <li> <strong>03:52</strong> SGLT2i definition, background, and why we now consider CV endpoints in diabetes<br> </li> <li> <strong>11:16</strong> Sponsor<br> </li> <li> <strong>12:00</strong> Tubuloglomerular feedback; Balloon analogy<br> </li> <li> <strong>17:40</strong> Other mechanisms for SGLT2i<br> </li> <li> <strong>23:05</strong> Back to the case; Risks from SGLT2i; Counseling and Monitoring<br> </li> <li> <strong>34: